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Abstract
Over 30% of patients with renal cell carcinoma (RCC) present with metastases, with median
survival of 2 years. Kidney injury molecule 1 (KIM-1) is a cell-surface glycoprotein expressed
by >90% of RCC tumours. Preliminary data mined from The Cancer Genome Atlas RNAsequencing database indicates that KIM-1 overexpression predicts overall survival in patients.
Here we sought to determine if tumour KIM-1 plays a role in RCC cell extravasation and
metastasis to the lungs. In vitro invasion and in vivo metastasis assays were performed to
investigate the metastatic potential of KIM-1-expressing cells, and RNA-seq was conducted to
identify differentially expressed genes between KIM-1+ and KIM-1neg cells.
Invasion was significantly decreased in vitro in both murine and human RCC cells that
expressed KIM-1. We concluded that KIM-1 inhibits RCC extravasation and metastasis to the
lungs, independent of adaptive immunity. RNA-seq analysis provided putative downstream
effectors of KIM-1.

Lay Summary
Metastasis is often the deadliest aspect of cancer and is characterized by the secondary spread
of cancer cells to distant sites of the body from the primary tumour. Over a third of patients
with renal cell carcinoma (RCC) - the most common form of kidney cancer - present with
metastases at the time of diagnosis. Kidney injury molecule 1 (KIM-1) is a cell-surface protein
expressed by >90% of RCC tumours. Preliminary data from our lab indicates that KIM-1
overexpression predicts overall survival in patients. Here we sought to determine if tumour
KIM-1 plays a role in RCC metastasis to the lungs - the most common site of metastasis in
RCC. The metastatic potential of KIM-1-expressing cells was investigated, and the differences
in gene expression between KIM-1+ and KIM-1neg cells were analyzed.
We concluded that KIM-1 inhibits RCC invasion and metastasis to the lungs, independent of
the adaptive immune system. RNA-sequencing analysis of the genes provided putative
downstream effectors of KIM-1, which could serve as novel therapeutic targets for the
treatment of metastatic RCC.
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Chapter 1

1

Introduction

1.1 Cancer
Cancer affects over 18 million people worldwide and is the second leading cause of death
globally. An increase in its incidence is also evident, and can be attributed to various risk
factors such as environment, poor diet, and inadequate physical activity (Ferlay,
Soerjomataram et al. 2015). In 2012 alone, GLOBOCAN estimated 14.1 million new cases
of cancer, and 8.2 million deaths due to cancer. In Canada, an estimated 2 in 5 Canadians
will develop cancer in their lifetime, and 1 in 4 will die from their disease (Canadian Cancer
Society 2015). Cancer is characterized as an uncontrolled proliferation and spread of
abnormal cells, which may lead to death (American Cancer Society 2016). Metastasis is
characterized by the spread of cancer cells from the primary tumour to distant tissues and
organs, and the establishment of a tumour at the secondary site (Fidler 2003). Metastases
are the most severe aspect of cancer, as they are the cause of the majority of deaths in
cancer patients. One of the most prominent barriers to the treatment of metastatic cancer is
the heterogeneity of cancer cells within the metastatic focus compared to the primary
tumour (Fidler 2003).
Hanahan and Weinberg have proposed that there are six characteristics that are essential
for the development and progression of all cancers, which they have termed the hallmarks
of cancer (Figure 1) (Hanahan and Weinberg 2011). Together, these six hallmarks allow
for the growth and dissemination of tumours: sustaining proliferative signaling, evading
growth suppressors, inducing angiogenesis, resisting cell death, enabling replicative
immortality, and activating invasion and metastasis. In recent years, they have suggested
the addition of two emerging hallmarks: reprogramming of energy metabolism, and
immune evasion. In addition to the hallmark characteristics, Hanahan and Weinberg have
posited that enabling characteristics such as genomic instability and tumour-promoting
inflammation are underlying factors that lead to the development of hallmark
characteristics.
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Research into the enigmatic steps of the invasion-metastasis cascade in recent years have
yielded a greater understanding on this critical step of cancer progression. Technological
advances have provided newer tools and models to investigate regulatory genes and
pathways involved in invasion and metastasis and shed light on what was previously poorly
understood.

Figure 1. The hallmarks of cancer
The six hallmarks of cancer first posited by Hanahan and Weinberg in 2000. These
hallmarks are necessary and essential capabilities that enable tumour growth and metastatic
dissemination. Adapted with permission from (Hanahan and Weinberg 2011).
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1.1.1

Invasion and Metastasis

Metastasis is a complex process, requiring the multi-step succession of events from the
development of the primary tumour, detachment and degradation of the ECM, intravasation
into the circulation, adhesion to the blood vessel wall, and finally extravasation into the
secondary tissue (Figure 2). Invasion and extravasation are the crucial and penultimate
steps in the spread of cancers.

Figure 2. Steps in the process of metastasis
Metastasis is a complex process that requires multiple steps to occur in succession. Cells
that successfully detach and enter the vasculature must survive various physical stressors
before arresting on the endothelium at distal sites. The ability for cancer cells to extravasate
is essential for the dissemination of cancer cells. Adapted with permission from (Wirtz,
Konstantopoulos et al. 2011).

1.1.2

Epithelial-mesenchymal-transition and Anoikis

One critically important process during the dissemination of carcinomas is the process of
epithelial-mesenchymal-transition (EMT) (Cao, Livas et al. 2016). EMT confers migratory
and invasive properties upon cancer cells, as well as the ability to degrade the extracellular
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matrix (ECM), allowing them to leave the primary tumour site and enter the vasculature
(Lambert, Pattabiraman et al. 2017). Once cancer cells enter the circulation, they must
overcome enormous physiological stressors before they can establish a metastatic focus at
a distant site. Disseminated cancer cells must be able to resist physical stressors such as
anoikis – a form of apoptosis due to detachment from the extracellular matrix – as well as
shear stress (Lambert, Pattabiraman et al. 2017). Anoikis is a tumour suppressing
mechanism that induces apoptosis in normal epithelial and endothelial cells that lose
contact with the ECM and suppresses proliferation of transformed cells at ectopic sites
(Rennebeck, Martelli et al. 2005). Resistance to anoikis is therefore essential to the survival
and migration of malignant cells in the vasculature. Anoikis resistance in cancer cells is
coupled with mechanisms that promote invasiveness which allow disseminated cells to
migrate to distal sites and establish metastases (Zhu, Sanchez-Sweatman et al. 2001,
Sakamoto, McCann et al. 2010). Along with the physical impediments, cancer cells will
encounter a plethora of cell types; among them, platelets, neutrophils, and NK cells, which
may serve to facilitate their passage or swiftly end their journey (Lambert, Pattabiraman et
al. 2017).

1.1.3

Arrest and Extravasation

One of the final obstacles malignant cells must overcome is the process of trans-endothelial
migration (TEM). Cancer cells must gain the ability to extravasate out of the bloodstream
and into the secondary tissue sites. Often, this occurs in small capillaries where the cancer
cells are physically confined to narrow luminal spaces, where they form stable interactions
with adhesion molecules on endothelial cells (Reymond, d'Agua et al. 2013). Studies have
shown that cancer cells may roll along the endothelium until stable adhesions form between
tumour cells and endothelial cells, by action of selectins, cadherins, and integrins (Miles,
Pruitt et al. 2008, Stoletov, Kato et al. 2010). Integrins are a group of cell-surface proteins
that enable cells to attach to the extracellular matrix (ECM), and sense whether adhesion
has occurred; β1-integrins specifically, have been shown to be crucial for mediating the
dynamic remodeling of endothelial cell junctions (Stoletov, Kato et al. 2010), through the
actions of Rho-GTPases (Miles, Pruitt et al. 2008).
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1.1.4

Rho-GTPases in Cancer

Rho-GTPases regulate cytoskeletal changes necessary for TEM by modulating actin
filament assembly (Braga, Del Maschio et al. 1999, Miles, Pruitt et al. 2008). Calciumdependent cadherin molecules are a family of molecules that contribute to cell-cell
adhesion. Cadherins line the extracellular domains of epithelial and endothelial cells and
hold cells together through homophilic interactions (Lozano, Betson et al. 2003). Actin
reorganization by Rho-GTPases alters the stability of endothelial cell-cell junctions –
known as adherens junctions – by interacting with the cytoplasmic ends of cadherin
molecules and disrupting the cell-cell interactions (Miles, Pruitt et al. 2008). Additionally,
Rho-GTPases may also regulate cancer cell motility through the same process of actin
reorganization. The disruption of cadherin-mediated adhesion is known to be one of the
most efficient mechanisms to achieve EMT, and Rho-GTPases have been shown to be
necessary for the maintenance of said cadherin-mediated adhesions (Braga 2000, Lozano,
Betson et al. 2003). Disruptions in both cadherin expression and function, as well as
deregulations in Rho-GTPases are thought to be required for TEM to occur.

1.1.5

Chemokines in Cancer

Chemokines also play a major role in invasion and metastasis, through their interactions
with G protein-coupled receptors (GPCR). It is well understood that certain cancer types
metastasize to specific secondary sites; prostate cancers preferentially metastasize to the
bone; lung cancers preferentially metastasize to the bone, liver and brain; breast cancers
preferentially metastasize to the lung, bone, liver, and brain; pancreatic cancers
preferentially metastasize to the liver; and kidney cancers preferentially metastasize to the
lungs, bone, and lymph nodes (Patanaphan, Salazar et al. 1988, Edlund, Sung et al. 2004,
Hess, Varadhachary et al. 2006, Bianchi, Sun et al. 2012). The seed-and-soil hypothesis
helps to partly explain these metastatic patterns through the understanding of the
expression of chemokines and their receptors between target sites and cancer cells. Of all
the chemokines known, the CXCR4/CXCL12 axis is most often implicated in tumour
progression, metastasis, and survival (Teicher and Fricker 2010). CXCR4 is an alphachemokine receptor that is normally absent or expressed at low levels, and only
overexpressed by malignant epithelial cells (Balkwill 2004). It is believed that the
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expression of CXCL12, also known as stromal-derived-factor-1 (SDF-1), by the target
endothelium attracts cancer cells expressing its cognate receptor CXCR4 and stimulates
their extravasation into secondary tissues. Studies have demonstrated the homing effect
that CXCL12 has on CXCR4+ cancer cells, showing that the CXCR4/CXCL12 axis has no
effect on adhesion, but significantly enhances tumour cell extravasation (which was
accompanied by the activation of Rho-GTPases) (Gassmann, Haier et al. 2009, Teicher and
Fricker 2010). The continued expression of these chemokines acts as a component of the
“soil” to retain the “seeds” that have made the pilgrimage from their primary tumours, and
promote angiogenesis, proliferation, and survival (Balkwill 2004, Teicher and Fricker
2010).

1.2 Renal Cell Carcinoma
Kidney cancer is the eighth most common form of cancer, and the twelfth leading cause of
deaths due to cancer (De, Otterstatter et al. 2014). Renal cell carcinoma (RCC) is the most
common form and accounts for over 90% of all cases of kidney cancer, with a 5-year
survival rate of 72% at the time of diagnosis (De, Otterstatter et al. 2014). Depending on
tumour progression, survival rates can be considerably lower in patients with metastatic
forms of the disease. These survival rates are drastically reduced in patients diagnosed with
stage IV of the disease – characterized by the metastasis of the tumour to distant sites – to
a mere 8% (American Cancer Society 2016). Due to a lack of effective screening tests for
the early stages of the disease, over 30% of patients present with metastases at the time of
diagnosis (Canadian Cancer Society 2015).

1.2.1

Risk Factors and Causes of RCC

Risk factors for RCC development include smoking, obesity, having first-degree relatives
with the disease, as well as a genetic mutation of the von Hippel-Lindau (VHL) protein
(De, Otterstatter et al. 2014). Of the RCC subtypes, the clear cell variant (ccRCC) accounts
for more than 80% of them (De, Otterstatter et al. 2014). The majority of ccRCCs have a
loss-of-function mutation in a gene on chromosome 3, which codes for the VHL protein, a
tumour suppressor known to mediate proteasomal degradation; one of its best known
targets is the alpha subunit of hypoxia inducible factors (HIF) (Kumar and Gabrilovich

7

2014). An accumulation of HIFs is associated with increased expression of vascular
endothelial growth factor (VEGF) and other angiogenic factors – conditions typically seen
in pre-malignant lesions (Kumar and Gabrilovich 2014, Schodel, Grampp et al. 2016). Two
isoforms of hypoxia-inducible factor alpha exist: HIF-1α and HIF-2α. Unique to ccRCC,
it has been shown that the two HIFα isoforms have opposing effects, with HIF-1α acting
as a tumour suppressor, and HIF-2α acting as an oncogene (Schodel, Grampp et al. 2016).
It has been suggested that there is a HIF switch during the development of RCC, where
HIF-1α drives the acute response to hypoxia, and HIF-2α drives the chronic response to
hypoxia (Koh and Powis 2012). Both HIF isoforms are activated under pseudohypoxic
conditions due to the loss of VHL, but there is a gradual loss of HIF-1α expression, coupled
with an increase in HIF-2α expression as tumour grade increases (Raval, Lau et al. 2005,
Koh and Powis 2012). The oncogenic HIF-2α has been implicated in the deregulation of
numerous target genes which affect proliferation including MYC, TGF-, VEGF, and p53
(Gunaratnam, Morley et al. 2003, Schodel, Grampp et al. 2016). Studies have demonstrated
the contrasting effects between the HIF isoforms, indicating that HIF-2α enhances tumour
growth, whereas HIF-1α inhibits c-Myc activity and RCC proliferation (Raval, Lau et al.
2005, Gordan, Lal et al. 2008). Given the fact that loss of HIF-1α was a notable hallmark
of renal cell carcinoma, downregulation of HIF-1α is believed to be important in the
pathogenesis of ccRCC. Indeed, Shen et al. (2011) found that the downregulation of HIF1α is associated with enhanced tumour growth in ccRCC, implicating it as a tumour
suppressor (Shen, Beroukhim et al. 2011).
Additionally, it has been shown that mutations in the VHL gene leads to upregulation of
CXCR4 expression in RCC (Staller, Sulitkova et al. 2003). VHL normally acts as a tumour
suppressor and negatively regulates CXCR4 expression via the degradation of HIF.
However, when mutated, or under hypoxic conditions, HIF can induce CXCR4 expression.
Overexpression of CXCR4 in RCC tumours is also associated with poor prognoses (Staller,
Sulitkova et al. 2003, Zagzag, Krishnamachary et al. 2005). Another study demonstrated
that the increased chemotactic response of CXCR4+ cancer cells towards CXCL12
expressing targets is dependent on the stabilization of CXCR4 transcripts and the activation
of HIF (Schioppa, Uranchimeg et al. 2003). Zagzag et. Al. found that the loss-of-function
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of VHL was responsible for the upregulation of both CXCR4 and its ligand CXCL12
(Zagzag, Krishnamachary et al. 2005).
G proteins and GPCRs such as Gα12 and Gα13 are known to promote proliferation and
metastasis in a variety of cancers (Dorsam and Gutkind 2007). In RCC, GTP-bound
(active) Gα12 has been shown to bind to exchange factor for ARF6 (EFA6) and activate the
ADP-ribosylation factor 6 (ARF6)-EFA6 pathway, which subsequently results in the
process of EMT and the promotion of invasion and metastasis (Hashimoto, Mikami et al.
2016). Gα12/13 have also been shown to regulate TGF-β1 (a known inducer of EMT)
expression through a Rho/Rac-dependent pathway via activating protein-1 (AP-1) (Lee,
Yang et al. 2009). It has been suggested that the upregulation of TGF-β1 results in
increased matrix metallopeptidase (MMP) expression – proteases which play major roles
in metastasis by degrading the ECM (Zhu, Liang et al. 2017). In support of this, a study
found that increased expression of MMPs in tumours is dependent on the activation of Rho
and Rac (Lozano, Betson et al. 2003). A study in breast cancer demonstrated that CXCR4mediated-chemotaxis and TEM of cancer cells is dependent on the coupling of Gα13 to
CXCR4, which activates the downstream cascade of Rho and promotes chemotaxis
towards CXCL12-expressing organs and subsequent extravasation (Yagi, Tan et al. 2011).
Although the study was done in breast cancer, the CXCR4/CXCL12 axis has also been
documented to play a pathological role in promoting invasion and metastasis in RCC
(Staller, Sulitkova et al. 2003, Zagzag, Krishnamachary et al. 2005). Lastly, Gα13 has been
shown to be responsible for proliferation, invasion, and EMT in RCC cells (Liu, Li et al.
2017). Inhibition of Gα13 by the micro-RNA MiR-30b-5p effectively suppressed metastatic
processes in RCC cell lines. Ultimately, there are many factors and molecules that
contribute to the metastasis of RCC cells, and a greater knowledge of these molecular
pathways would be beneficial in developing therapies to treating metastatic RCC.

1.2.2

Current Therapies for RCC

One of the major barriers to treating RCC currently is the ineffective detection of
neoplasms at early stages of the disease, as one third of patients present with metastasis at
diagnosis (Custodio, Joaquim et al. 2012). In localized forms of the disease, where the
neoplasms are relatively small and metastases are not present, surgery is the most effective

9

form of therapy (de Vivar Chevez, Finke et al. 2014). Radical or partial nephrectomy in
these patients significantly improves their 5-year survival rate. In patients with metastatic
forms however, surgery alone yields no improvement on survival, only palliation and
symptom relief (de Vivar Chevez, Finke et al. 2014). In metastatic cases, the most effective
form of treatment is surgery in conjunction with molecular-targeted therapy and
immunotherapy (de Vivar Chevez, Finke et al. 2014).

1.2.2.1

Molecular Targeted Therapy

Molecular targeted therapies act on molecules in the RCC pathway which are specific to
the disease, hence minimizing toxicities and adverse effects on other organs and tissues (de
Vivar Chevez, Finke et al. 2014). Silencing of the VHL gene in RCC results in the
overexpression of VEGF which contributes to the angiogenic nature of the disease (de
Vivar Chevez, Finke et al. 2014). VEGF and molecules along the VEGF pathway have
been the focus of molecular targeted therapy and the mainstay treatment for metastatic
RCC (Su, Stamatakis et al. 2014). Sunitinib is part of a class of drugs known as receptor
tyrosine kinase inhibitors (rTKI), which exert their effects through the inhibition of VEGF
receptors (Su, Stamatakis et al. 2014). Sunitinib has become a first-line treatment in
advanced RCC patients due to its relatively high response rate of 40% and an extended
survival of 40 months (Finke, Rayman et al. 2013). Studies have also found that sunitinib
can deplete peripheral myeloid-derived suppressor cells (MDSC) and improve T cell
functions in hosts (Finke, Rayman et al. 2013, Su, Stamatakis et al. 2014). Resistance to
rTKIs arises in patients over time and is currently an area of focus.
The serine-threonine protein kinase mammalian target of rapamycin (mTOR) is a critical
molecule in a multitude of biological pathways such as proliferation, metabolism, protein
synthesis, and angiogenesis (de Vivar Chevez, Finke et al. 2014). Its expression is
associated with worse outcomes in local and metastatic RCC patients (de Vivar Chevez,
Finke et al. 2014). Two well-tested mTOR inhibitors: temsirolimus, and everolimus, are
used as second-line treatment options in cases of disease progression after treatment with
rTKIs and have demonstrated improvement in overall survival (Su, Stamatakis et al. 2014).
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1.2.2.2

Immunotherapy

Immunotherapy is a form of cancer treatment which harnesses the host’s own immune
system to help eradicate the cancer. RCC is particularly amenable to immunotherapy owing
to its immunogenic nature. While RCC elicits a strong immune response, RCC tumours
evade immune destruction through a variety of mechanisms that ultimately render the
activated immune cells entering the tumour dysfunctional (Massari, Santoni et al. 2015).
Over a decade ago, high-dose interleukin-2 (IL-2) and interferon-gamma (IFN-γ) were the
cytokine treatments of choice for metastatic renal cancer (Massari, Santoni et al. 2015). IL2 promotes T cell proliferation and differentiation, whereas IFN-γ exerts anti-angiogenic
effects, and promotes dendritic cell maturation (Raman and Vaena 2015). Although highdose IL-2 therapy appeared promising, only a small population of patients showed stable
curative responses. Due to the significant treatment-related toxicities associated with highdose IL-2 therapy, only carefully selected patients were suitable for treatment (Raman and
Vaena 2015). Clinical research has shifted towards alternative forms of immunotherapy
with less adverse effects such as immune checkpoint inhibitors.
Ground breaking research and identification of the checkpoint inhibitors cytotoxic T
lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) have invited new
possibilities for immunotherapy (Dong, Strome et al. 2002, Massari, Santoni et al. 2015).
It is thought that CTLA-4 exerts its inhibitory effects during the priming and activation
phase of T cells, whereas PD-1 exerts its inhibitory effects on effector T cells in the tumour
microenvironment (TME) (Fife and Bluestone 2008, Massari, Santoni et al. 2015). PD-1
has two ligands: PD-L1 and PD-L2. PD-L1 is expressed on many cells throughout the
body, whereas PD-L2 is only expressed on macrophages and dendritic cells (Massari,
Santoni et al. 2015). PD-1 is expressed on many immune cells such as T cells, B cells, and
NKT cells to prevent auto-immunity in inflammatory sites; a mechanism which tumours
exploit by expressing PD-L1 on their surface to inhibit T cell responses and avoid immune
destruction (Massari, Santoni et al. 2015). Research has also shown that PD-L1 is
aberrantly expressed on primary and metastatic RCC tissue, and that its expression is
associated with worse patient outcomes (Thompson, Dong et al. 2007). Research into PD1/PD-L1 blockade therapy has shown promising results, with a well-studied anti-PD-1
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antibody drug, nivolumab, producing a significant response rate of 27% in patients with
RCC (Massari, Santoni et al. 2015). Nivolumab restores anti-tumour activity in patients
and has been demonstrated to exert its activity within the TME (Philips and Atkins 2014).
It has also been shown to produce relatively low levels of toxicity, accompanied with
durable responses.

1.2.3

Murine Model for Renal Cell Carcinoma

The murine model for renal cell carcinoma is the most widely used model for studying the
disease as it is the most analogous to the human form of the disease, thus treatments and
responses can be effectively evaluated (Murphy and Hrushesky 1973). Two models are
commonly used to study tumours in mice: the xenograft model and the syngraft model,
which require immunodeficient and immunocompetent mice, respectively (White and
Olsson 1980). The xenograft model requires either human RCC cell lines or a tumour graft
from human samples, whereas in a syngraft model, the Renca cell line – derived from a
spontaneously arising RCC cell line in BALB/c mice – is commonly used (Murphy and
Hrushesky 1973). A disadvantage of cell lines is that they produce homogenous tumours,
whereas human tumours are often heterogenous. An autochthonous murine model for
ccRCC that recapitulates human ccRCC had long eluded scientists but recent
groundbreaking work by Harlander et al. identified that mice harbouring combined Vhl,
Trp53 and Rb1 mutations caused spontaneous ccRCC (Harlander, Schonenberger et al.
2017). The study found that the mice developed genetically distinct ccRCC tumours and
were molecularly similar to the human disease, thus providing a useful tool to investigate
pre-clinical therapeutic studies.

1.2.3.1

Xenograft Model

In the xenograft model, fresh human tumours or established human cell lines can be
successfully xenografted into immunodeficient mice and can propagate into solid tumours
(White and Olsson 1980). The three most commonly used immunodeficient mouse strains
are: nude athymic mice, which lack T cells; severe combined immunodeficient (SCID)
mice, which lack B and T cells; and non-obese diabetic (NOD)/SCID mice, which lacks
both B and T cells, and has decreased functional macrophages, granulocytes, and NK cells
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(White and Olsson 1980). Human RCC cell lines are widely used in murine models to
accurately study and characterize tumour development and progression, and has been
important to understanding the cell biology of renal cancer (Morton and Houghton 2007).
Currently, multiple human RCC cell lines are available: ACHN, A-498, 786-O, 769-P,
Caki-1, and Caki-2 (Morton and Houghton 2007, Brodaczewska, Szczylik et al. 2016). Of
the aforementioned cell lines, only A-498, 786-O, and 769-P have a VHL mutation, making
them ideal choices to study ccRCC specifically. 786-O was one of the earliest established
RCC cell lines and is most commonly used, as it also expresses elevated VEGF levels
(Shinojima, Oya et al. 2007), a characteristic of ccRCC. The 769-P cell line also expresses
high levels of VEGF, however, its use in xenograft models has been constrained as studies
found it lacked tumourigenicity when injected subcutaneously or intravenously into mouse
models (Kozlowski, Fidler et al. 1984, Miyake, Goodison et al. 2013). A major limitation
of the xenograft model is the fact that the mice are immunodeficient, thus making it
impossible to study the immune component of RCC and its interactions with the established
tumours.

1.2.3.2

Syngraft Model

The syngraft model involves the establishment of immunologically compatible tumours in
immunocompetent mice and is advantageous as it makes studying the interaction between
immune cells and the tumours, as well as tumour progression and metastasis possible. The
use of the Renca cell line in the RCC mouse model has been studied extensively since the
70s (Murphy and Hrushesky 1973). The growth and progression of the solid tumours
follow a predictable timeline, as does the spread of secondary tumours. The growth and
dissemination of the RCC tumours in this model are also consistent and reproducible, and
strongly recapitulate the disease in humans, making the Renca cell line a popular model to
use (Murphy and Hrushesky 1973). Furthermore, the Renca cell line reflects the
immunogenic nature of human RCC, as repeated tumour challenges in mice resulted in
decreased incidence.
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1.2.4

Murine Model for Metastasis

To study metastasis in mice, three tumour transplant models are commonly used: the
experimental metastasis model, the spontaneous metastasis model, and the genetically
engineered mouse model (Gomez-Cuadrado, Tracey et al. 2017). For the purposes of this
thesis, only the former two models will be discussed.

1.2.4.1

Experimental Metastasis Model

Experimental metastasis models allow for the rapid and reproducible development of
metastases in specific organs (Gomez-Cuadrado, Tracey et al. 2017). Depending on the site
of study, cancer cells can be injected intravascularly, and the route of injection determines
the site of colonization (Khanna and Hunter 2005). For example; intravenous injections in
the lateral tail vein result in lung metastases; intracardiac injections result in brain and bone
metastases; and intraperitoneal injections result in ovarian metastases (Gomez-Cuadrado,
Tracey et al. 2017). A major limitation of the experimental model is that they only reflect
the late stages of the metastatic process, particularly the arrest and extravasation steps, and
subsequent development of tumours in ectopic sites.

1.2.4.2

Spontaneous Metastasis Model

Spontaneous metastasis models on the other hand, allow for the metastatic disease to be
studied in a manner that mimics the disease progression in humans. The cancer cells are
transplanted orthotopically, and the entire metastatic cascade can be monitored as the
primary tumour grows and disseminates naturally to the secondary site (Gomez-Cuadrado,
Tracey et al. 2017). Orthotopic models can therefore recapitulate the disease in humans
better as it allows cancers to interact with the tissue of origin and elicit natural responses,
which also include the earlier stages of metastasis such as invasion and intravasation
(Francia, Cruz-Munoz et al. 2011). Spontaneous models however, require greater expertise
to implant the cancer cells properly in the orthotopic site (Gomez-Cuadrado, Tracey et al.
2017).
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1.3 Kidney Injury Molecule
Kidney injury molecule-1 (KIM-1), also known as T cell immunoglobulin mucin domain
1 (TIM-1) and hepatitis A virus cellular receptor 1 (HAVCR1), belongs to the family of
TIM proteins, which are type-1 cell surface glycoproteins involved in the regulation of T
cell activation and tolerance (Han, Alinani et al. 2005), and is a highly upregulated
marker in the proximal tubule after renal injury (Brodaczewska, Szczylik et al. 2016). It
has a heavily glycosylated ectodomain that is cleaved and released into the lumen, and
can be detected in the urine and blood of humans, mice, and rats following kidney injury
(Ichimura, Bonventre et al. 1998, Sabbisetti, Waikar et al. 2014).

1.3.1

Function

Phosphatidylserine is expressed on the surface of apoptotic and necrotic cells (Fadok,
Savill et al. 1992, Zargarian, Shlomovitz et al. 2017). KIM-1 is a phosphatidylserine
receptor that transforms proximal tubular epithelial cells (PTEC) into semi-professional
phagocytic cells that can recognize and enhance the clearance of apoptotic cells and
necrotic cells, thus making it an important molecule in the regulation of the immune
response after kidney injury (Ichimura, Asseldonk et al. 2008, Arai, Kitada et al. 2016).
The rapid clearance of dead cells prevents excessive inflammation and auto-immune
responses against intracellular antigens released from dying cells (Kobayashi, Karisola et
al. 2007). Normally, KIM-1 preferentially binds and internalizes apoptotic cells over
necrotic cells, but in the presence of the protein apoptosis inhibitor of macrophages (AIM),
KIM-1-mediated clearance of necrotic cells is significantly increased (Molitoris 2014,
Arai, Kitada et al. 2016). It has been shown that following kidney injury, AIM expression
increases in the tubular lumen, where it binds necrotic debris and mediates phagocytosis
by PTECs expressing KIM-1 (Arai, Kitada et al. 2016).
It has been suggested that KIM-1 can elicit opposite effects in the kidney; KIM-1 is
protective early in acute kidney injury (AKI) (Yang, Brooks et al. 2015), but sustained
expression leads to kidney fibrosis, progressive interstitial kidney inflammation, and
chronic kidney disease (CKD), thus providing a potential link between AKI and CKD
(Humphreys, Xu et al. 2013).
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1.3.2

Role of KIM-1 in RCC

Following acute kidney injury, PTECs (including those expressing KIM-1) undergo dedifferentiation, proliferation, and re-differentiation in order to repair the tubular epithelium
(Humphreys, Xu et al. 2013). However, the de-differentiation of PTECs is heterogenous in
nature, and only some of the regenerating cells express KIM-1 (Kusaba, Lalli et al. 2014).
Similar to injured PTECs, RCC cells also exist in a state of de-differentiation (Shimazui,
Oosterwijk-Wakka et al. 2000). Not surprisingly, KIM-1 is expressed in >90% of human
RCC tissue samples (Bonventre 2014, Zhang, Mashni et al. 2014).
KIM-1 is highly expressed in the two most prevalent forms of RCC: clear cell RCC, and
papillary RCC, and can serve as a non-invasive biomarker for the early diagnosis of the
disease through the detection of the shed ectodomain in the urine of patients (Han, Alinani
et al. 2005, Zhang, Mashni et al. 2014). Studies have shown that significantly greater levels
of KIM-1 were detected in the urine samples of ccRCC patients compared with patients
with prostate carcinoma or control subjects (Bonventre 2014, Zhang, Mashni et al. 2014).
In contrast, KIM-1 is absent in normal kidney tissue, and it has been demonstrated that
patients who tested positive for KIM-1 expression pre-nephrectomy showed either
complete disappearance or marked reduction in KIM-1 expression post-nephrectomy (Han,
Alinani et al. 2005, Bonventre 2014). It has recently been shown that plasma KIM-1
concentrations can serve as a reliable biomarker for the prediction of RCC onset up to 5
years before diagnosis (Scelo, Muller et al. 2018). Combined, these studies indicate that
KIM-1 is a sensitive and specific biomarker for the early detection of RCC.
One study has shown that overexpression of KIM-1 promotes tumour growth in human
769-P cells, whereas silencing of the gene led to a reduction in cancer cell proliferation
(Cuadros, Trilla et al. 2014). The same study found that KIM-1 activates the STAT-3/IL6/HIF-1α axis in ccRCC, which indicates KIM-1s involvement in the pathway for tumour
growth and angiogenesis. KIM-1 expression on RCC cells is associated with increased
levels of transforming growth factor beta (TGF-β), which has been shown to promote
metastatic invasion (Bostrom, Lindgren et al. 2013, Sabbiseti 2014). In contrast, a study
previously published by our lab demonstrated that KIM-1 expression on TECs inhibits
Gα12, which consequently results in the inhibition of downstream RhoA – a small GTPase
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involved in invasion and metastasis (Ismail, Zhang et al. 2016). We however have not
examined the role of KIM-1 and G12 in RCC cells. Therefore, the precise role that KIM1 plays in RCC remains poorly understood.

1.4 Rationale, Objective, and Hypothesis
1.4.1

Rationale

RCC is the most common form of kidney cancer, and makes up over 90% of all cases (De,
Otterstatter et al. 2014). Patients with stage IV metastatic RCC have a frighteningly low 5year survival rate of only 8%, of whom comprise of over 30% of patients at the time of
diagnosis (Canadian Cancer Society 2015). Current available therapies fall short due to the
development of resistances and toxicities, compounded with suboptimal response rates in
clinical trials (Massari, Santoni et al. 2015, Raman and Vaena 2015). Targeted therapies
such as mTOR inhibitors, and VEGF inhibitors have been limited by resistance and toxicity
(Su, Stamatakis et al. 2014), and immunotherapies such as PD-1/PD-L1 inhibitors have
demonstrated limited response rates in clinical trials (Massari, Santoni et al. 2015). Surgery
is often the most effective form of treatment in patients with non-metastatic RCC, but only
offers palliation and symptom relief in patients with the metastatic form of the disease (de
Vivar Chevez, Finke et al. 2014). There is hence an urgent need for novel therapeutic
targets for the treatment of metastatic RCC.
In RCC, studies have found that KIM-1 is overexpressed in over 90% of RCC tumours,
which includes the 2 most prevalent and aggressive forms of the disease: clear cell and
papillary (Bonventre 2014, Zhang, Mashni et al. 2014). This overexpression is important
since it is absent in healthy kidneys, and either absent or markedly reduced in patients that
have undergone nephrectomy. The biological significance of this overexpression is still
unclear; it is unknown whether KIM-1 overexpression promotes the disease, or if KIM-1
is overexpressed because of the disease.
The Cancer Genome Atlas (TCGA) is a publicly available cancer genomics program that
has characterized the molecular profiles of over 20,000 primary cancers and profiled 33
types of cancers (National Cancer Institute 2006). We mined TCGA database in hopes of
understanding how KIM-1 expression correlates with clinical outcome in patients. From
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our unpublished data, we found that the high KIM-1 expressing patients had surprisingly
greater overall survival compared with low KIM-1 expressing patients (Appendix A 1).
Despite KIM-1 being absent in healthy kidneys, and it being overexpressed in the majority
of RCC tumours, there appears to be an apparent protective effect in human patients.
There remains a vacuum in understanding on the role that KIM-1 plays in the metastasis
of RCC in humans. KIM-1 appears to be a promising candidate to study and may lead to
the development of novel therapeutic targets for the treatment of metastatic RCC. Given
that metastasis is the most common cause of death in patients with RCC, and that KIM-1
expression is predictive of overall survival, KIM-1 may play a role in regulating metastasis
in RCC. Determining whether KIM-1 plays a role in the development of metastatic RCC
and elucidating the mechanisms behind its effects in RCC would be beneficial to
understanding metastasis in the disease.

1.4.2

Objective and Hypothesis

The objective of this study was to determine the role that KIM-1 plays in the metastatic
cascade of RCC and to elucidate the mechanism behind the action of KIM-1 and its
downstream effectors. This study could ultimately help identify KIM-1 as a novel
therapeutic target for the treatment of metastatic RCC.
We hypothesized that KIM-1 inhibits the metastatic potential of RCC cells. The specific
aims of the work outlined in this thesis were; 1) To determine whether KIM-1 inhibits
metastatic capabilities in vitro; 2) To determine whether KIM-1 inhibits invasion and
metastasis in vivo; 3) To determine whether KIM-1-mediated inhibition of metastasis is
dependent on adaptive immunity, and; 4) Elucidate genes that are differentially expressed
between KIM-1+ and KIM-1neg cells. We predicted that; KIM-1 expression on RCC cells
inhibits cancer cell invasion and metastasis both in vitro and in vivo; KIM-1-mediated
inhibition of invasion and metastasis in vivo is independent of any contribution from the
adaptive immune system, and; KIM-1 expression inhibits downstream effectors involved
with invasion and metastasis.
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Chapter 2

2

Materials and Methods

2.1 Generation of Stable Cell Lines
2.1.1

Plasmid Preparation and Transfection

Dr. Lawrence Kane (University of Pittsburgh, Pittsburgh, PA) generously provided the
pCDEF3-mTim-1 (mKim-1) plasmid (Addgene plasmids # 49206; Cambridge, MA) and
the parental pCDEF3 plasmid. DH5α competent cells transformed with either the pCDEF3mKim-1 plasmid or pCDEF3 vector alone were grown overnight in LB media (1% w/v
tryptone, 0.5% w/v yeast extract, 1% w/v NaCl) with 100 mg/ml ampicillin at 37° C with
shaking. Plasmids were isolated using Geneaid midi plasmid kit (Geneaid Biotech Ltd.,
New Taipei City, Taiwan) following the manufacturer’s protocol. Renca cells were plated
in 6-well plates in complete medium and incubated until cells reached approximately 70%
confluency. Renca cells stably expressing Kim-1 (Renca-pCDEF3-Kim-1) or pCDEF3
(Renca-pCDEF3) were generated by transfecting them with 2.5 μg of either pCDEF3-Kim1 or pCDEF3 vector using 6 μl Lipofectamine® 2000 (ThermoFisher Scientific). After 24
h, the Renca cells were moved to a 15-cm plate and subjected to G418 selection (400 μg/ml)
48-h post-transfection. Renca cells were cultured continuously in the presence of G418
until non-transfected cells were completely killed. G418-resistant colonies were picked by
aspirating medium, washing cells with 1x phosphate-buffered saline (PBS; 137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HOP4, 1.47 mM KH2PO4, pH 7.4) solution, and incubating
cells with pre-cut pieces of filter paper soaked in 0.25% trypsin-EDTA (Invitrogen) for 5
minutes in a 37°C, 5% (v/v) CO2 incubator. Filter paper with attached cells were picked
and grown in 24-well plates in full medium containing 400 μg/ml G418 until cells reached
confluency. Individual colonies were then expanded, and Kim-1 expression was confirmed
using western blot.

2.1.2

Stable Expression of Kim-1 Using Lentiviral Particles

Lentivirus ORF particles containing a vector with the murine Kim-1 gene, Havcr1 and a
puromycin resistance gene (MR203831L3V; Origene, Rockville, MD) were used to
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transduce Renca cells (herein referred to as Kim-1+ Renca). A control lentivirus ORF
particle containing the same vector but lacking the Kim-1 transcript (PS100092V; Origene)
was used as a control (Kim-1neg Renca). The optimal concentration of lentiviral particles
to use was determined based on testing various multiplicities of infection (MOIs), which
is the number of transducing lentiviral particles per cell. To calculate the total transducing
units (TU) needed; the total number of cells per well is multiplied by the desired MOI.
Then, the total TU needed is divided by the titer of the virus purchased in TU/ml to give
the total mL of lentiviral particles to be added to each well. Renca cells were seeded on a
24-well plate in full medium and incubated for 24 h when 75% confluency was reached.
The medium was aspirated and replaced with full medium containing 8 μg/mL of polybrene
(Santa Cruz Biotechnology) and the appropriate number of lentiviral particles (either
control particles or particles containing the Kim-1 transcript). After 24 h, the medium was
aspirated and replaced with full medium. 72 h post-transduction, stable cell lines were
selected for using medium supplemented with puromycin. Medium was aspirated and
replaced with full medium containing 2 μg/ml of puromycin every 2–3 days for two weeks.
After two weeks, cells transduced with Kim-1 ORF lentiviral particles were screened for
Kim-1 expression via western blot and PCR.

2.1.3

shRNA Knock-down of Endogenous KIM-1 Using Lentiviral
Particles

Lentiviral particles containing three human KIM-1-specific constructs encoding shRNA
(sc-61691; Santa Cruz) were used to knockdown KIM-1 in the 769-P and 786-O cell line
(herein referred to as 769-P-/786-O-shKIM-1). Control transduction was done using
control scrambled shRNA lentiviral particles (769-P-/786-O-shcontrol) (sc-108080; Santa
Cruz). 769-P/786-O cells were plated on a 12-well plate in full medium and incubated for
24 h until 75% confluency was reached. The medium was aspirated and replaced with 1
mL total volume of full medium containing 8 μg/mL of polybrene (Santa Cruz
Biotechnology) and 25 μL of lentiviral particles (either shKIM-1 or shcontrol lentiviral
particles). After 24 h, the medium containing polybrene and lentiviral particles was
aspirated and replaced with complete medium. 72-h post-transduction, stable cell lines
expressing the respective shRNA were isolated via selection with puromycin. Medium was
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aspirated and replaced with full medium containing 4 μg/ml of puromycin every 2–3 days
for two weeks. After two weeks, knockdown of KIM-1 in 769-P and 786-O cells was
confirmed via western blot and PCR.

2.2 Western Blot
Confluent monolayers of the respective cells (Renca, 769-P and 786-O) were lysed with
ice cold 4% sodium dodecyl sulfate (SDS) and centrifuged at 15,000 x g for 10 minutes.
The supernatants were collected for western blot analysis. Protein concentrations were
determined using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific) and samples
were prepared such that they contained 50 μg of total protein. Proteins were separated by
SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (EMD
Millipore, Billerica, MA). Membranes were blocked with blocking buffer (Tris-buffered
saline, 0.1 % Tween-20 (ThermoFisher Scientific), and 5% non-fat dried milk (Carnation))
for 1 h. Membranes were then incubated overnight at 4°C with primary antibodies:
extracellular domain of human KIM-1 (AKG; Dr. Bonventre, Harvard Medical School,
Cambridge, MA), extracellular domain of mouse Kim-1 (AF1817; R&D systems,
Minneapolis, MN), or GAPDH (6C5; Santa Cruz Biotechnology). Membranes were
washed and incubated with the appropriate horseradish peroxidase-conjugated secondary
antibody (dilution 1:30000; Jackson ImmunoResearch Laboratories, West Grove, PA) for
1 h at room temperature in blocking buffer. Proteins were visualized using Luminata Forte
Western HRP Substrate (EMD Millipore) and developed using the FluorChem M system
(ProteinSimple, San Jose, CA).

2.3 RNA Extraction and cDNA Synthesis
Cell and tissue samples were collected in TriPure isolation reagent (Roche Diagnostic,
Basel, Switzerland). 200 μL of chloroform per 1 mL of TriPure reagent used was added to
samples and then mixed vigorously. The samples were incubated for 10 minutes at room
temperature and then centrifuged at 12,000 x g for 20 minutes at 4°C. The aqueous layer
was carefully recovered in a fresh tube and an equal volume of isopropanol was added to
the aqueous layer for precipitation. The mixture was vortexed briefly, incubated at room
temperature for 10 minutes, and then centrifuged at 12,000 × g for 10 minutes at 4°C. The
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supernatant was removed from the tube and the pellet was washed with 70% ethanol, and
subjected to centrifugation at 7,500 x g for 5 minutes at 4°C. After removal of the
supernatant, the pellet was resuspended in DEPC-treated water and quantified with
spectrophotometry (260 and 280 nm; MultiskanTM GO Microplate Spectrophotometer;
ThermoFisher Scientific). 1 μg of total RNA and 4 μL of qSCRIPT cDNA SuperMix
(Quanta Biosciences, Gaithersburg, MD) were used to generate cDNA using the
MyCyclerTM thermal cycler (Bio-Rad, Hercules, CA).

2.3.1

Real Time-PCR (RT-PCR)

RT-PCR was performed using the StepOnePlus Real-Time PCR System (Applied
Biosystems, Waltham, MA) and SYBR Green detection (ThermoFisher Scientific). The
reaction mixture had a total reaction volume of 20 μL, which consisted of 10 μL of SYBR
Green Master Mix, 0.2 μL of each 10 μM forward and reverse primer for the gene of
interest, 4.6 μL of DEPC treated water, and 5 μL of cDNA diluted in DEPC-treated water
at a ratio of 1:10. Primers for KIM-1 and GAPDH are shown in Table 1 (Integrated DNA
Technologies, Coralville, IA). Normalization of the target gene was performed to GAPDH
to compensate for inter-PCR variations. Relative gene expression was calculated using the
2-ΔΔCt method.

2.3.2

Standard PCR

The reaction mixture had a total volume of 25 μL, which consisted of cDNA, DEPC treated
water, 200 μM of forward and reverse primer for the gene of interest, 2 U/rxn of Taq DNA
polymerase (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 0.2 mM of dNTP mix (Clontech
Laboratories, Mountain View, CA), and 1x PCR Reaction Buffer (Invitrogen). Primers for
KIM-1 and GAPDH are shown in Table 1 (Integrated DNA Technologies). Amplicons
were resolved using a 1% agarose gel via gel electrophoresis in 1x TBE buffer
(Tris/borate/EDTA; 0.09 M Tris (hydroxymethyl) Aminomethane, 0.09 M Boric Acid, 0.1
mM EDTA). Amplicons were visualized with ethidium bromide and UV light using the
FluorChem M system (ProteinSimple). Target genes were normalized to GAPDH.
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2.1 Cell Culture
The murine RCC line, Renca, was purchased from ATCC (CRL-2947). Cells were
maintained according to ATCC recommendations. Cells were cultured in RPMI-1640
medium, supplemented with L-glutamine and 25 mM HEPES (Lonza, Walkersville, MD),
10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), 2 mM L-glutamine
(ThermoFisher Scientific, Waltham, MA), 1 mM sodium pyruvate (ThermoFisher
Scientific), 0.1 mM non-essential amino acids (ThermoFisher Scientific), and 5%
penicillin streptomycin (PS; Invitrogen). Stable Renca cell lines were maintained with 2
mM puromycin dihydrochloride (Sigma-Aldrich, St. Louis, MO). The human RCC cell
lines, 786-O and 769-P, were purchased from ATCC (CRL-1932). Cells were cultured in
DMEM medium, supplemented with L-glutamine, sodium pyruvate, and phenol red
(Wisent Bioproducts, Saint-Jean Baptiste, QC), 10% FBS, and 5% PS. Stable 786-O cell
lines were maintained with geneticin sulfate (G418; Santa Cruz Biotechnology, Santa Cruz,
CA). All cells were maintained in a 37⁰ C, 5% (v/v) CO2 incubator.

2.2 Migration and Invasion Assay
Cell migration and invasion were used as surrogates for metastatic potential of RCC cells
in vitro. Transwell culture plates with 8.0-μm-pore-size polycarbonate membrane filter
inserts with 6.5 mm diameter (Corning, NY) were used to perform migration and invasion
assays. Plate wells were filled with 800 µL of serum-free media (SFM) or complete media
with 10% FBS (Renca in RPMI; 786-O in DMEM). Renca cells were cultured to a
confluency of ~80% and resuspended in SFM at a concentration of 2x105 cells/mL. 786-O
cells were cultured to 100% confluency, starved for 24h prior to collection, and
resuspended in SFM at a concentration of 1x105 cells/mL. 200 µL of cells were seeded in
the Transwell insert and plates were incubated for 24 h in a 37⁰ C, 5% (v/v) CO2 incubator.
For invasion assays, Transwell inserts were coated with 200 µL of Matrigel (1:100 dilution
in SFM; BD Biosciences, NJ) 24 h prior to seeding of cells. After incubation, media was
aspirated from the inserts and wells, and lightly blotted dry using cotton swabs.
Subsequently, 1 mL of cold methanol was added to each well, and inserts were replaced
and incubated at RT for 5 minutes to fix the cells. Methanol was aspirated, and 1 mL of
eosin dye (Sigma-Aldrich) was added to each well and incubated at RT for 5 minutes. This
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process was repeated using a secondary toluidine blue dye (Sigma-Aldrich). Wells were
then washed twice at RT with 2 mL of distilled water for 5 minutes each. Inserts were then
removed and placed upside down to dry on benchtop for 30 minutes. Using a scalpel blade,
insert membranes were carefully cut out, fixed on a glass slide and allowed to dry overnight
at RT. Light microscopy was used to quantify the migrated and invaded cells. All assays
were performed in triplicate.

2.3 Extravasation Efficiency Assay in the CAM of Chick
Embryos
Methods and protocols for CAM extravasation model was conducted by Marie Sarabusky
as previously described in the laboratory of Dr. Hon Leong (then) at the Lawson Health
Research Institute (Kim, Williams et al. 2016). Renca and 769-P cells were plated on cell
culture flasks and grown until 80% confluency was obtained. Medium was aspirated, cells
were washed with 1x PBS, and then cells were incubated for 5 minutes with 0.25% trypsinEDTA in a 37°C, 5% (v/v) CO2 incubator. Cells were centrifuged for 5 minutes at 500 x
g, the supernatant was aspirated, and cells were resuspended in 1 mL of 1x PBS. Cells were
fluorescently labeled using 1 μL of CellTracker dye (ThermoFisher Scientific) and
incubated on ice for 5 minutes. Cells were centrifuged for 5 minutes at 500 x g and the
supernatant was aspirated. A day 13 embryo was placed under a dissecting scope with
white light illumination in order to visualize the veins in the CAM. The cell suspension
was drawn up into a microinjector and 1x105 KIM-1+ or KIM-1neg cells were injected into
the vein of the CAM. Following the injection, two filter square windows were placed on
the surface of the embryo at sites away from the injection site. A wide-field fluorescent
microscope at 10x objective was used to count and record all the cells within each square
window immediately after injection. All cells at this time point (T = 0 h) are intravascular.
24 h later, the fluorescent microscope was used again to count and record the number of
intravascular and extravascular cells (T = 24 h). The extravasation efficiency was
determined by dividing the number of extravasated cells at T = 24 h by the number of
intravascular cells at T = 0 h in each of the square windows (Kim, Williams et al. 2016).
The mean extravasation efficiency for all foil windows on each embryo was then
determined. To obtain intravital images of intravascular and extravasated cells, the CAM
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was additionally injected with lectin-DyLight 649 (Vector Laboratories, Burlington, ON)
and Dextran-Alexa 555 (ThermoFisher Scientific) and imaged using a confocal microscope
(Olympus, Tokyo, Japan) with the 60x objective at T = 0 h and T = 24 h.

2.4 Mice
Female wild-type (WT) BALB/c mice were purchased from Charles River Laboratory
(Wilmington, MA) and maintained in the pathogen-free animal facility at Western
University. Mice were kept in standard shoebox cages with access to pellet food and bottled
tap water in rooms maintained at constant temperatures (22⁰ C) with 12-h light/12-h dark
cycles. Immune-deficient C129-Rag (Rag1-/-) mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and maintained in the pathogen-free barrier facility at
Western University. Mice were kept in pathogen-filtered shoebox cages with access to
pellet food and water through a filtered nozzle, and maintained in similar room conditions.
Experimental mice were monitored every 2 days for physiological and behaviour changes.
All mice were euthanized using CO2 chambers, and post-mortem procedures were
conducted as described. All animal protocols (2010-230, later renewed 2018-147) and
experiments were approved by Western University’s Animal Use Subcommittee in
compliance with the guidelines set by the Canadian Council of Animal Care.

2.5 Experimental Metastasis Model
2.5.1

Intravenous Injection of RCC cells

To study experimental metastasis of RCC cells into the lungs, 6-10-week-old female WT
BALB/c mice were injected with Renca cells via lateral tail vein. Renca cells were cultured
in cell culture flasks up to a confluency of 80%. Media was aspirated, and cells were
washed with 5 mL of cold 1x PBS, and then incubated with 10 mL of cold 1x PBS at room
temperature (RT) for 10 minutes. PBS was aspirated and replaced with 3 mL of 0.25%
trypsin-EDTA (Wisent Bioproducts) for 5 minutes in a 37⁰ C, 5% (v/v) CO2 incubator.
Cells were then flushed with 6 mL of complete RPMI-1640 media to dislodge adherent
cells, which were then collected and centrifuged at 500 x g for 5 minutes, and the
supernatant was subsequently aspirated. Cells were counted using trypan blue and a
hemocytometer, and viable cells were then resuspended at a concentration of 2.5x106
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cells/mL in sterile 1x PBS. Mice were restrained using a cylindrical mouse restrainer
(Stoelting, Wood Dale, IL) and injected with 200 µL (5 x 105 cells) of Renca cells via the
lateral tail vein, using a ½ inch 28-gauge insulin syringe (Becton Dickinson, Franklin
Lakes, NJ). Mice were monitored after 24 h, and then every 2 days until day 17, at which
point, they were euthanized using a CO2 chamber. To study whether KIM-1-mediated
inhibition of metastasis is dependent on adaptive immunity, Renca or 786-O cells were
instead injected into the tail veins of immune-deficient BALB/c (Rag1-/-) mice in the same
manner as described above.

2.5.2

Staining of Lungs and Visualization of Metastatic Nodules

We used a modified version of the protocol described by Zimmerman et al. (Zimmerman,
Hu et al. 2010) to stain the lungs of mice injected either intravenously or orthotopically
with RCC cells and for visualization of metastatic nodules. Euthanized mice were pinned
down on their dorsal side, and their chest cavity was opened up along the sternum using
scissors to expose the lungs and trachea. The trachea was clamped down at the highest
possible point with tweezers, and 2 mL of 15% India black ink (diluted in distilled water)
was slowly injected into the trachea below the clamp, expanding the lungs and turning
them black. Lungs were excised, detached from the heart and thymus, and placed in a
beaker of distilled water for 5 minutes to wash off excess ink. The lungs were then
transferred to a 15 mL Falcon tube (ThermoFisher Scientific) containing 5 mL of Fekete’s
solution (Appendix A 2) to expose the metastatic tumour tissue as white nodules. Lungs
were incubated overnight at 4⁰ C before being washed with 1x PBS and metastases counted
under a low power light microscope.

2.6 Spontaneous Metastasis Model
To study the spontaneous metastasis of RCC cells to the lungs, Renca cells were
orthotopically injected into kidney capsules of 10-14-week-old female WT BALB/c mice.
Mice were first anesthetized with Ketamine/Xylazine (100 mg/kg, 16 mg/kg), and given
slow-release buprenorphine (1 mg/kg) for pain control. The drugs were injected
subcutaneously according to institutional guidelines. Injection site (left flank) was shaved
and prepared with 5% povidone-iodine antiseptic. An incision (~1.5-2 cm) was carefully
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made using sterile scalpel and scissors to not penetrate the peritoneum. The dermis layer
and peritoneum were then carefully separated. The kidney was identified underneath the
spleen and held in place using forceps. Carefully, 30 µL of cell suspension (2 x 105 cells
in a 1:1 ratio with Matrigel) was injected into the subcapsular space of the kidney and held
in place for a minute while a heat lamp was placed overhead to solidify the Matrigel. The
incision was closed, and the animal was returned to its cage and monitored until it
recovered to parameters set by institutional guidelines. Once the injections were completed,
the mice were monitored after 24, 48, and 72 h, and then every 2 days after until day 17.
Mice were then sacrificed, and lungs were stained and collected as described previously.

2.7 RNA Sequencing
RNA sequencing was performed by London Genomics Centre under the guidance of Dr.
Rob Hegele at the Robarts Research Institute (Western University). RNA extraction and
cDNA library synthesis were performed as described above with Kim-1+ and Kim-1neg
Renca cells. Adapter sequences specific to the Illumina sequencing platform was used.
Libraries were sequenced using the Illumina NextSeq 500 sequencer (Illumina Inc., San
Diego, CA). A bioinformatic pipeline was built using the Partek Flow software (Partek
Inc., St. Louis, MO) to compare differences in gene expression between Kim-1+ and Kim1neg Renca cells. A heat map was generated by changing parameters to only include genes
with significant differences with p < 0.05 and exclude fold-changes between -1.5 and 1.5
(Figure 9). Gene pathway and gene set enrichment were performed to determine biological
pathways and specific genes relevant to invasion and metastasis. The same stringency
values used to generate the heat map were applied. The pathways and genes are displayed
in Table 2 and 3.

2.8 Statistical Analysis
Differences in means between KIM-1+ and KIM-1neg groups for all results were analyzed
using unpaired two-tailed t-tests. Statistical significance was defined as: *, p < 0.05; **, p
< 0.01; ***, p < 0.001. Data was represented as mean ± SEM. Statistical analyses were
performed using the GraphPad Prism, version 8 software.
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Chapter 3

3

Results

3.1 Renca cells expressing Kim-1 exhibited decreased
metastatic potential in vitro
To understand the metastatic potential of Renca cells in vitro, Transwell migration and
invasion assays were performed (Figure 3). Renca cells were seeded in the Transwell
inserts, and SFM or complete media (RPMI with 10% FBS) was loaded (underneath) into
the plate wells. For invasion assays, the Transwell insert membranes were coated with
Matrigel prior to cell seeding. Kim-1+ Renca cells showed significantly reduced migratory
capability compared with Kim-1neg Renca cells in both the SFM group (22.67 vs. 40.33),
and the 10% group (51 vs. 76.67), respectively (n = 3; SFM, p = 0.0049; 10%, p = 0.0307)
(Figure 3A). Kim-1+ Renca cells also exhibited significantly fewer invading cells
compared with Kim-1neg Renca cells, in the SFM group (35.33 vs 50.33), and in the 10%
group (34 vs. 49.33), respectively (n = 3; SFM, p = 0.0006; 10%, p = 0.0005) (Figure 3B).
Together, these data demonstrate that Kim-1 expression inhibits the migration and invasion
of Renca cells in vitro.
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Figure 3. Transwell migration and invasion assay of Kim-1+ and Kim-1neg Renca cells.
(A) Migration assay of Kim-1+ and Kim-1neg Renca cells (n=3) (B) Invasion assay of Kim1+ and Kim-1neg Renca cells (n=3). (C) Images of migration assay Transwell insert
membranes (10X) (D) Images of invasion assay Transwell insert membranes (10X). 2 x
105 Renca cells were seeded in serum-free RPMI media in Transwell inserts on top of wells
filled with serum-free or complete RPMI media supplemented with 10% FBS. Plates were
incubated at 37⁰ C for 24h. Transwell insert membranes for invasion assay were coated
with Matrigel 12h prior to seeding. Data is represented as mean number of cells ± SEM
(A; SFM, p = 0.0049; 10%, p = 0.0307. B; SFM, p = 0.0019; 10%, p = 0.0028, Unpaired
two-tailed t-test). SFM, serum-free media; 10%, complete RPMI media supplemented with
10% FBS.
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3.2 KIM-1 expression on 786-O cells inhibits invasion in
vitro
To understand the metastatic potential of human RCC (786-O) cells in vitro, Transwell
migration and invasion assays were performed (Figure 4). 786-O cells were seeded in the
Transwell insert, and SFM or complete media (DMEM with 10% FBS) was loaded into
the plate wells. No significant differences were observed between 786-O-shcontrol and
786-O-shKIM-1 cells in the migration assay (Figure 4A). 786-O-shcontrol cells displayed
significantly fewer number of invaded cells compared with 786-O-shKIM-1 cell in the
SFM group (42 vs. 98; p = 0.0006) and in the 10% group (22 vs. 36.7; p = 0.0396) (Figure
4B). Together, these data indicate that KIM-1 expression inhibits the invasion of 786-O
cells in vitro.
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Figure 4. Transwell migration and invasion assay of 786-O-shcontrol and 786-OshKIM-1 cells.
(A) Migration assay of 786-O-shcontrol (KIM-1+) and 786-O-shKIM-1 (KIM-1neg) cells
(n=3) (B) Invasion assay of 786-O-shcontrol (KIM-1+) and 786-O-shKIM-1 (KIM-1neg)
cells (n=3). (C) Images of migration assay Transwell insert membranes. (D) Images of
invasion assay Transwell insert membranes. 1 x 105 786-O cells were seeded in serumfree DMEM media in Transwell inserts on top of wells filled with serum-free or complete
DMEM media supplemented with 10% FBS. Plates were incubated at 37⁰ C for 24h.
Transwell insert membranes for invasion assay were coated with Matrigel 12h prior to
seeding. Data is represented as mean number of cells ± SEM (B; SFM, p = 0.0006; 10%,
p = 0.0396, Unpaired two-tailed t-test). SFM, serum-free media; 10%, complete DMEM
media supplemented with 10% FBS.
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3.3 Kim-1 expression decreases cancer cell extravasation
efficiency of murine Renca cells
To determine the ability of cancer cells to extravasate out of capillaries, fluorescently
labeled Renca cells were injected into the vein in the CAM of a day 13 chick embryo. An
image of a chick embryo on day 13 reveals the tumor cell injection site and two filter square
windows, in which cells were counted at T = 0 h and T = 24 h using a fluorescent
microscope (Figure 5A). Figure 5B contains a typical confocal image of the fluorescently
labeled components of the vasculature (endothelial walls and vessel lumen space) with
Renca cells labeled in green to depict intravascular and extravasated cells. Intravascular
cells had an irregular morphology and were retained within the blood vessel (top panel),
whereas extravasated cells had a rounded morphology and appeared to be present in the
extracellular stroma (lower panel) (Figure 5B). Kim-1+ Renca cells had an extravasation
efficiency of 47.78% which was significantly decreased compared to Kim-1neg Renca
control cells, which had an extravasation efficiency of 60.73% (n = 6; p <0.05) (Figure
5C). Overall, Kim-1 expression appears to decrease extravasation efficiency of the murine
Renca cell line.

3.4 KIM-1 expression decreases cancer cell extravasation
efficiency of human 769-P cells
Fluorescently labeled human RCC (769-P) cells stably expressing shRNA targeting KIM1 or control shRNA were injected into the vein in the CAM of a day 13 chick embryo. 769P-shcontrol cells had an extravasation efficiency of 30.08% which was significantly
decreased compared to 769-P-shKIM-1 cells, which had an extravasation efficiency of
47.94% (n = 6; p < 0.0001) (Figure 5C). These data appear to indicate KIM-1 expression
decreases extravasation efficiency of human 786-O cells.
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Figure 5. Chick chorioallantoic membrane (CAM) extravasation assay of 769-P and
Renca cells.
(A) Image of chick embryo with representative location of tumour cell injections (needle)
and filter square windows (white arrows). (B) CAMs used for confocal imaging were
injected with fluorescent dyes to label the endothelial walls (purple) and the vessel lumen
space (red), in addition to the fluorescently labeled cells (green). (C) 0.5 x 105 769-P
(shcontrol/KIM-1+ and shKIM-1/KIM-1neg) and Renca (Kim-1+ and Kim-1neg) cells were
injected into the vein in the CAM of a day 13 chick embryo (n = 6/ group). Two filter
square windows were placed at sites on the CAM that were away from the injection site.
Fluorescent cells were counted in the windows at T = 0 h and T = 24 h using a fluorescent
microscope. Scale bar is 20 μm. Data is represented as mean of extravasation efficiency in
percentage per group ± SEM (769-P, p < 0.001; Renca cells, p < 0.05, Unpaired two-tailed
t-test). CAM, chorioallantoic membrane. *Methods and data adapted from Marie
Sarabusky.
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3.5 KIM-1 expression on Renca cells inhibits metastasis in
an in vivo experimental metastasis model
To investigate the role of Kim-1 expression in the metastasis of Renca cells, we injected 5
x 105 Kim-1+ Renca or Kim-1neg Renca cells intravenously via the tail vein into 6-10-weekold female WT BALB/c mice. In this experimental metastasis model, intravenously
injected cancer cells invaded the lung tissue and developed metastatic nodules (GomezCuadrado, Tracey et al. 2017). Mice were sacrificed after 17 days (or if moribund), and
their lungs were excised for examination of metastatic nodules following staining with 15%
India black ink and Fekete’s solution. Mice injected with Kim-1+ Renca cells developed
significantly fewer lung nodules compared to mice injected with Kim-1neg Renca cells (n =
5; 256.6 vs. 429.4, p = 0.0226) (Figure 6). These data demonstrate that Kim-1-expressing
Renca cells inhibit the development of lung metastases in an experimental metastasis
model.

Figure 6. Kim-1 expression on Renca cells decreases experimental lung metastases in
WT BALB/c mice
Approximately 5 x 105 Renca (Kim-1+ and Kim-1neg) cells were injected into 6-10-weekold female WT BALB/c mice via lateral tail vein (n = 5/ group). Mice were sacrificed in
CO2 chambers after 17 days. Lungs were removed, stained with 15% India black ink and
counterstained with Fekete’s solution to visualize metastatic tumour tissue. Data is
represented as mean number of metastatic nodules ± SEM (p = 0.0226, Unpaired two-tailed
test). WT, wild-type.
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3.6 Kim-1 expression does not alter the metastatic potential
of Renca cells in an in vivo spontaneous metastasis
model
We injected 2 x 105 Kim-1+ Renca or Kim-1neg Renca cells orthotopically into the
subcapsular space of the kidney of 8-12-week-old female WT BALB/c mice to investigate
the effect of Kim-1 expression on Renca cell metastasis in a clinically relevant spontaneous
metastasis model. No statistically significant differences were found between Kim-1+ and
Kim-1neg cells at day 17 (Figure 7). The majority of injections yielded < 12 metastatic
nodules, therefore, meaningful results could not be determined.

Figure 7. Kim-1 expression on Renca cells has no effect on the development of
spontaneous lung metastases.
Approximately 2 x 105 Renca (Kim-1+ and Kim-1neg) cells were injected into the
subcapsular space of the kidney of 8-12-week-old female WT BALB/c mice (n = 4/ group).
Mice were sacrificed in CO2 chambers after 17 days. Lungs were removed, stained with
15% India black ink and counterstained with Fekete’s solution to visualize metastatic
tumour tissue. Data is represented as mean number of metastatic nodules ± SEM. WT,
wild-type.
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3.7 Kim-1 expression on Renca cells inhibits metastasis in
vivo independent of adaptive immunity
To determine whether the observed Kim-1-mediated inhibition of metastasis was
dependent on the adaptive immune system, we repeated the above described experimental
metastasis model using immune-deficient BALB/c (Rag1-/-) mice as hosts instead of
immune competent (WT) BALB/c mice. As described previously, 5 x 105 Renca cells were
injected via the lateral tail vein of Rag1-deficient BALB/c mice. Mice injected with Kim1+ Renca cells developed significantly fewer metastatic nodules than mice injected with
Kim-1neg Renca cells (n = 5; 33.2 vs. 135.4, p = 0.036) (Figure 8A). These data show that
Kim-1 decreases metastasis to the lungs in Renca cells independent of adaptive immunity.

3.8 KIM-1 expression on 786-O cells inhibits metastasis in
vivo independent of adaptive immunity
To study the effect of KIM-1 expression on the metastasis of human cells, the above
experiment was repeated with 786-O cells rather than Renca cells. Mice injected with 786O-shcontrol cells developed significantly fewer metastatic nodules than mice injected with
786-O-shKIM-1 cells (n = 4 & 5; 130.6 vs. 339.3, p = 0.0013) (Figure 8B). Overall, these
data indicate that KIM-1 expression in 786-O cells inhibits metastasis independent of the
adaptive immune system.
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Figure 8. KIM-1 expression on Renca and 786-O cells decreases experimental lung
metastases in Rag1-deficient mice
(A) Lung metastatic nodules from mice injected with Renca cells (n = 5). (B) Lung
metastatic nodules from mice injected with 786-O cells (n = 4 & 5). 5 x 105 Renca (Kim1+ and Kim-1neg) and 786-O (KIM-1+ and KIM-1neg) cells were injected into 6-10-weekold female immune-deficient Rag1-/- mice via lateral tail vein. Mice were sacrificed in CO2
chambers after 17 days. Lungs were removed, stained with 15% India black ink and
counterstained with Fekete’s solution to visualize metastatic tumour tissue. Data is
represented as mean number of metastatic nodules ± SEM (Renca, p = 0.036; 786-O, p =
0.0013, Unpaired two-tailed test).
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3.9 RNA-sequencing of Renca cell lines to elucidate the
mechanism of KIM-1-dependent inhibition of metastasis
In an attempt to identify a putative mechanism to explain how KIM-1 may be inhibiting
metastasis in RCC cells, we performed RNA-sequencing to study the differential
expressions of genes and gene pathways between Kim-1+ Renca or Kim-1neg Renca cells
(Figure 9). Analysis of the RNA-seq data using broad pathway filtration techniques helped
determine gene pathways which displayed significant differences between the two cell
lines (Table 2). Stringency values were set to only include pathways with a p-value < 0.05.
When analyzing the data for differences in specific genes between Kim-1+ Renca or Kim1neg Renca cell lines, we determined a list of genes and the fold-change differences of Kim1+ cells relative to Kim-1neg cells (Table 3). The stringency values were set to only include
p-values < 0.05 and exclude fold-changes between -1.5 to +1.5. The highlighted pathway
and gene in each table were scrutinized further and found to possess functions relevant to
invasion and metastasis.
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Figure 9. Heatmap of genes upregulated or downregulated by Kim-1 expression in
Renca cells.
Heatmap of genes differentially expressed between Kim-1+ and Kim-1neg Renca cells
generated through RNA sequencing. Only genes with significant differences (p < 0.05) are
shown. Genes with fold-changes between -1.5 and +1.5 were excluded. Gene names are
aligned along the left and gene clustering is shown on the right. Sample names are labelled
along the bottom. Red represents upregulated genes. Green represents downregulated
genes. Black represents unchanged expression.
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Table 1: Mouse and human oligonucleotide PCR primer sequences
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Table 2: Gene set enrichment and pathway analysis with significant differences
between Kim-1+ and Kim-1neg Renca cell lines.

* Pathway highlighted in yellow was determined to be the most relevant to invasion and
metastasis and will be investigated further
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Table 3: Genes with significant fold-change differences between Kim-1+ and Kim-1neg
Renca cell lines.

* Gene highlighted in yellow was determined to be the most relevant to invasion and
metastasis and will be investigated further
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Chapter 4

4

Discussion

4.1 Major Findings
4.1.1

KIM-1 inhibits invasion of Renca and 786-O cells in vitro

Overall, our in vitro studies suggest KIM-1 inhibits the invasive potential of RCC cells. In
the migration assay, Kim-1+ Renca cells migrated far less than their Kim-1neg Renca
counterparts both in the presence and absence of complete media with 10% FBS (Figure
3A). However, there appears to have been greater numbers of migrated cells in the FBS
group compared with the SFM group. From the Renca invasion assay, the addition of FBS
did not appear to elicit any differences in migration (Figure 3B). This may be due to the
fact that Matrigel contains many proteins and growth factors such as collagen IV, laminin,
epidermal growth factor, fibroblast growth factor, and TGF-β, among many others
(Hughes, Postovit et al. 2010). The abundance of these growth factors could potentially
diminish the chemotactic effect of the FBS medium in the plate wells.
In contrast, there were no observed differences in the number of migrated cells between
786-O shcontrol and 786-O shKIM-1 in the migration assay (Figure 4A). Similar to the
Renca migration assay however, the FBS chemoattractant group had increased numbers of
migrated cells. Interestingly, in the invasion assay, significantly fewer 786-O shcontrol
cells invaded compared with the 786-O shKIM-1 cells in both the SFM group and the FBS
group (Figure 4B). These results were unexpected as we predicted that both the migration
and invasion assays would reflect what was observed in the Renca cells. We also expected
the FBS group to elicit a greater chemotactic response compared with the SFM group. A
possible explanation for the difference observed between the SFM group and the 10%
group is that the calf serum used exerts inhibitory effects on the invasive potential of human
786-O cells in the presence of matrix proteins. In contrast to our experiment design, others
used FBS containing media only when performing 786-O cell invasion assays (Chang,
Chen et al. 2011, Zhao, Luo et al. 2015). Overall, our data has led us to conclude that KIM1 expression on Renca and 786-O cells inhibits invasion in vitro. This conclusion is
consistent with what had been reported by Cuadros et al. who showed that 786-O cells with
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enhanced KIM-1 shedding results in increased invasiveness in vitro (Cuadros, Trilla et al.
2013).

4.1.2

KIM-1 expression inhibits the extravasation of RCC cells out
of the capillaries

Our CAM experiments demonstrated that KIM-1 expression significantly inhibited the
extravasation of RCC cells (Figure 5). In both human 769-P cells and murine Renca cells,
the KIM-1-expressing group showed reduced extravasation capabilities. Our results here,
however, contradict findings from a recent study demonstrating that KIM-1 overexpression
in 769-P cells resulted in increased proliferation but showed mixed results in terms of
migration (Cuadros, Trilla et al. 2014). The study found that migration in KIM-1
overexpressing cells was delayed at early time points but proceeded to migrate faster than
control cells at later time points. Our results clearly demonstrate that KIM-1 inhibits the
invasive potential of 769-P and Renca cells in an in vivo model, and suggests an inhibitory
role for KIM-1 in cancer cell extravasation.

4.1.3

Longer time points are required for spontaneous metastasis
models

Our data from the pilot spontaneous metastasis experiment were inconclusive as there were
no significant differences between the Kim-1+ and Kim-1neg groups (Figure 7). In both
groups (n=4), only one mouse developed meaningful counts of metastatic nodules. Our
lack of results is likely due to insufficient time for metastases to develop post-injection as
well as decreased tumour load. We followed the protocol described by Feldman et. al.
(2016) who also studied renal metastases to the lungs by Renca cells in mice given regular
or high-salt diets (Feldman, Ding et al. 2016), however, we injected 2 x 105 cells instead
of 2.5 x 105 cells. In their study, Feldman et al. sacrificed the mice 14 days after Renca cell
implantation into the subcapsular space of the kidneys. Injection into the subcapsular space
is a commonly accepted method for assessing renal metastasis and has been found to be
the most advantageous site for RCC implantation (Naito, von Eschenbach et al. 1986,
Matin, Sharma et al. 2010). A recent study injected RCC cells directly into the kidney, but
extended the end-point to 23 days before harvesting the lungs (Murphy, James et al. 2017).
This study also proposed the use of luciferase-expressing Renca cells so that
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bioluminescent imaging (BLI) could be used to visualize and quantify the growth and
spread of cancer cells. We have generated luciferase-expressing Renca cells in our
laboratory to repeat these experiments so that we can utilize BLI.

4.1.4

KIM-1-mediated inhibition of metastasis occurs independent
of adaptive immunity

Using a murine experimental metastasis model, we showed that Kim-1 expression on
Renca cells inhibited metastasis of cancer cells to the lungs (Figure 6). Our experimental
metastasis data suggest that Kim-1 expression inhibits mechanisms involved in the arrest
and extravasation of Renca cells out of the vasculature and into the lungs. When we
repeated the experimental metastasis model in immune-deficient (Rag1-/- BALB/c) mice,
we found that the differences between KIM-1 expression persisted in the absence of an
adaptive immune system in these mice. KIM-1+ RCC cells developed significantly fewer
metastatic lung nodules compared with KIM-1neg cells in both the murine (Renca) and
human (786-O) models, demonstrating that KIM-1 expression results in decreased
metastatic potential (Figure 8). Our data indicate that the KIM-1-mediated inhibition of
metastasis is inherent to the cancer cells themselves, and not a by-product of the adaptive
immune system targeting KIM-1+ cells in a more efficient way. Thus, the metastatic
phenotype is driven by a loss of KIM-1 expression in RCC cells.
Our lab demonstrated that during renal ischemia-reperfusion injury and phagocytosis,
KIM-1 binds to Gα12 and suppresses its activity (Ismail, Zhang et al. 2015, Ismail, Zhang
et al. 2016). Gα12 has been demonstrated to promote proliferation and metastasis in RCC
through various pathways (Lee, Yang et al. 2009, Hashimoto, Mikami et al. 2016). GTPbound-Gα12 can bind to EFA6, which can go on to activate the Arf6-EFA6 pathway
resulting in EMT (Hashimoto, Mikami et al. 2016). Gα12 has also been shown to promote
the expression of TGF-β1 through a Rho/Rac-dependent pathway, which ultimately leads
to the induction of invasion and EMT (Lee, Yang et al. 2009). Rho-GTPases are
downstream effectors of Gα12 and are crucial to the processes of actin remodeling and
invasion (Braga, Del Maschio et al. 1999, Lozano, Betson et al. 2003, Miles, Pruitt et al.
2008). Findings made by Ismail et. al. regarding Gα12 have implications for metastasis in
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RCC. For instance, the inhibition of Gα12 by KIM-1 would result in the inhibition of
downstream Rho, which results in the inhibition of invasive properties in tumour cells.
Our current findings regarding KIM-1 in RCC contrast that of several groups who have
claimed that KIM-1 promotes tumour growth and exacerbates cancer progression.
Microvascular invasion (MVI) is defined by the invasion of cancer cells into the endothelial
walls of small blood vessels and is associated with higher risks of metastases and death in
patients with ccRCC (Eisenberg, Cheville et al. 2013, Santiago-Agredano, AlvarezKindelan et al. 2013). Mijuskovic et. al. (2018) showed that high degrees of MVI were
associated with significantly increased expression of tumour tissue KIM-1, and that urinary
KIM-1 was associated with worse disease prognoses and higher TNM staging (Mijuskovic,
Stanojevic et al. 2018). Their study therefore suggests that KIM-1 is associated with greater
risks of invasion and metastases in patients with ccRCC. A recent study has also suggested
that KIM-1 silencing in 786-O cells results in tumour growth inhibition (Xu, Sun et al.
2018). Xu et al. found that silencing KIM-1 decreased proliferation in vitro and in vivo,
suggesting KIM-1 is tumourigenic. In this study, KIM-1-knocked-down 786-O cells
injected into nude mice developed smaller tumours compared with control 786-O cells –
which endogenously expressed KIM-1.

4.1.5

KIM-1 as a tumourigenic molecule

Multiple studies have also identified KIM-1 as a possible early biomarker for the detection
of clear cell and papillary RCC, and associated its expression with the disease’s tumour
grade (Han, Alinani et al. 2005, Zhang, Mashni et al. 2014, Mijuskovic, Stanojevic et al.
2018). One study demonstrated an association between urinary KIM-1 and tumour KIM1, suggesting that high levels of urinary KIM-1 are indicative of worse prognosis and
higher tumour-node-metastasis (TNM) grades (Mijuskovic, Stanojevic et al. 2018). The
same study demonstrated that urinary KIM-1 levels were significantly reduced postnephrectomy, again suggesting a link between urinary KIM-1 and disease progression.
Another study found that KIM-1 was expressed on the majority of clear cell, papillary, and
metastatic RCC tumours, and may serve as a diagnostic marker for these renal cancers (Lin,
Zhang et al. 2007). It has also been previously shown that KIM-1 expression in human
769-P cells promotes tumour growth through the activation of the IL-6/STAT3/HIF-1α
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axis, and the silencing of the gene results in reduced proliferation and angiogenesis
(Cuadros, Trilla et al. 2014). Studies have demonstrated that KIM-1 promotes
tumourigenesis by increasing the secretion of tumour-promoting factors such as TGF-β and
IL-6 (Bostrom, Lindgren et al. 2013, Sabbiseti 2014). Elevated TGF-β expression has been
associated with the loss of VHL, and has been implicated in the processes of invasion and
EMT (Bostrom, Lindgren et al. 2013). Furthermore, it is well established that the majority
of ccRCC have a loss-of-function mutation in the VHL gene, which leads to the
accumulation of HIF and the subsequent increase in VEGF and other angiogenic factors
(De, Otterstatter et al. 2014, Kumar and Gabrilovich 2014, Schodel, Grampp et al. 2016).
Taken together, our findings about the role of KIM-1 in RCC pathogenesis are in stark
contrast with what had been suggested to be the role of KIM-1 in RCC. Although these
studies appear to contradict our findings, they merely focus on a different side of the same
coin. The studies focused on the proliferation and progression of the primary tumour as
well as the overall disease, but our data assessed the metastatic aspect of the disease and
suggests a role for KIM-1 in regulating the metastatic cascade.

4.1.6

Rap1 and Rab27B may be regulated by KIM-1

In this study, we wanted to elucidate the mechanism by which KIM-1 inhibits metastasis
in RCC. Utilizing RNA-sequencing, we were able to determine genes and pathways that
are differentially expressed between Kim-1+ and Kim-1neg Renca cells (Figure 9). Analysis
of the data through the Partek Flow software allowed us to narrow down genes and
pathways that were significantly different between the cell types. We set stringency values
to only include p-values < 0.05. The list of significantly different gene pathways is shown
in Table 2. From the gene pathways, we found that the Rap1 signaling pathway is highly
involved in the processes of invasion and metastasis (Caron 2003, Shah, Brock et al. 2019).
Rap1 is a small GTPase part of the Ras protein family and serves as a regulator of cellular
functions such as adhesion, and integrin activation (Zhang, Wang et al. 2017). Rap1 has
also been implicated in regulating cadherin-mediated adhesion between endothelial cells
to form adherens junctions and strengthen cell attachment (Pannekoek, Kooistra et al.
2009). It has been suggested that Rap1 antagonizes Ras-mediated proliferation and
transformation independently via its complex signaling pathway. Rap1 exhibits pleiotropic
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effects in different cancers, exerting oncogenic effects in melanoma, breast cancer, and Bcell lymphomas (Gao, Feng et al. 2006, Lin, Tan et al. 2010, McSherry, Brennan et al.
2011), and tumour suppressor effects in bladder, lung, and brain cancers (Lyle,
Raaijmakers et al. 2008, Zhang, Wang et al. 2017). The regulation of adherens junctions
and actin remodeling by Rap1 have implicated it in the progression of metastasis. Rap1GAP (GTPase-activating proteins) is known to inactivate Rap1 by converting GTP-bound
Rap1 to GDP-bound Rap1 (Kim, Gersey et al. 2012). Evidence suggests that Rap1
promotes invasion and metastasis in RCC, and Rap1-GAP is downregulated in RCC. In
contrast, another study demonstrated that Rap1-GAP levels vary between human RCC cell
lines, and is moderately expressed in 786-O cell lines relative to 6 other RCC cell lines,
suggesting that 786-O cells are relatively less invasive (Wu, Zhang et al. 2011). Taken
together, we have speculated a role for Rap1 in the invasion and metastasis of Renca cells
which should be further explored to determine whether it is upregulated or downregulated,
and whether the metastatic phenotype in Kim-1neg cells is due to upstream effects of Kim1 on the Rap1 pathway.
When we analyzed the RNA-seq data for specific genes that had significant fold-changes
between Kim-1+ and Kim-1neg Renca cells, we found that Rab27B displayed a significant
decrease in fold-change in Kim-1+ cells compared with Kim-1neg cells (Table 3). Like
Rap1, Rab27B is a member of the Ras-family of GTPases, and has been shown to be
involved in proliferation and invasion in several cancers, with their downregulation
conferring reduced invasiveness and improved prognoses (Li, Jin et al. 2017, Yang, Ye et
al. 2017, Wu, Niu et al. 2019). In lung adenocarcinoma studies, Rab27B expression was
significantly higher in cancer cells compared with noncancerous cell lines, and has been
suggested as a negative prognostic marker for lymph node metastasis and TNM staging
(Zhang, Fan et al. 2018). Studies have suggested that Rab27B regulates the
phosphatidylinositol 3 kinase (PI3K)/AKT pathway in hepatocellular carcinoma (Yang, Ye
et al. 2017). The PI3K/AKT pathway has been shown to regulate multiple aspects of cancer
including metastasis (Manning and Cantley 2007), and has also been implicated in RCC
and is known to be highly activated in the disease (Guo, German et al. 2015). Interestingly,
a recent study investigated Rab27A and Rab27B (the 2 subunits of Rab27) and
demonstrated that Rab27A – but not Rab27B – was significantly associated with TNM
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staging and could serve as a potential prognostic marker for RCC (An, Song et al. 2019).
In context with our findings, another possible mechanism could be that Kim-1
downregulates Rab27B, resulting in decreased proliferation and invasion of Renca cells.
The role of Rab27B in RCC is unclear, but it may serve as a promising target to focus
future research on.

4.2 Limitations
4.2.1

Transwell migration and invasion assays

Transwell chemo-invasion assays were developed over two decades ago and continue to
serve as a quick and quantitative model to study invasive cell migration and cell
interactions with basement membranes (Albini and Noonan 2010). It remains a relevant
model for investigating cancer cell invasiveness in vitro as it has been demonstrated that
only tumourigenic cells are able to penetrate Matrigel layers (Albini and Noonan 2010,
Hughes, Postovit et al. 2010). Serum-free media was used in these pilot experiments to
assess the baseline migration of the cells relative to FBS – a standard chemotactic agent in
Transwell assays. Fetal bovine serum is one of the most well-known and widely used
serums, and contains a multitude of macromolecules, nutrients, attachment and
dissemination factors, as well as hormones and growth factors (Shah 1999, Gstraunthaler
2003). It is often used as a supplement in cell culture, and as a chemotactic agent in
migration and invasion assays for RCC (Liu, Zhang et al. 2016, Huang, Wei et al. 2017).
This is in line with the standard method found in the literature, which typically uses FBS
containing medium as the chemoattractant in the plate wells. Additionally, SFM controls
are not typically necessary for migration and invasion assays. To elicit more profound and
physiologically relevant responses, the addition of chemokines or conditioned media is
sometimes used in place of FBS (Justus, Leffler et al. 2014, Jeong, Han et al. 2016,
Gabrielyan, Neumann et al. 2017). It has been reported that media conditioned from
fibroblasts or cells of choice contribute cytokines, growth factors, metabolites, and ECM
proteins to the media, which offer greater growth and chemotactic capacities for cells
(Jeong, Han et al. 2016). Alternatively, some studies stimulate cells with chemokines or
engineer chemokine overexpression prior to seeding in the Transwell insert to upregulate
migratory processes (Xuan, Feng et al. 2017, Zhuang, Cao et al. 2018).
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A major limitation of the Transwell assay as a method to study extravasation is that it is
only an in vitro model and can only investigate the invasiveness of cancer cells at the
Matrigel interface. As such, it only simulates 2D interactions between cancer cells and the
Matrigel over circular pores and offers a limited scope of what occurs in 3D at tight
endothelial junctions in vivo during arrest (Kim, Williams et al. 2016). Additionally, the
effect of hemodynamics and plasma proteins on migrating cells cannot be investigated
using this model as the in vitro model lacks the full repertoire of cell types present in the
blood. Another limitation is that the time points set for incubation are arbitrary and are not
representative of the invasion process in vivo which is not as forgiving if cells fail to
migrate across the endothelium.

4.2.2

CAM extravasation assay

The CAM extravasation assay overcame the limitations of the Transwell assay by
providing a rapid and quantitative assessment of extravasation in an in vivo model. The
assay was conducted by Marie Sarabusky, who followed the protocol for the CAM
extravasation model as described (Kim, Williams et al. 2016). The assay allowed us to
specifically investigate the ability of cancer cells to arrest and extravasate out of capillaries
into surrounding tissues. It also allowed us to visualize the process of extravasation by
using fluorescent dyes to label the cells and the vasculature. Additionally, the low cost of
this assay allowed for greater sample sizes with adequate power and allowed for the valid
determination of statistical significance.
However, a limitation of the CAM assay is that the use of fluorescently labelled cells – a
technique that requires relatively more complex and expensive equipment – is fundamental
for visualizing the extravasation of cancer cells from the blood vessels (Kim, Williams et
al. 2016). Another limitation to consider is the fact that this model was designed to
investigate extravasation of mammalian cells but is applied in an avian embryo. Certain
plasma proteins, hormones, and growth factors specific to mammalian cells may not be
present in this model. There may not be a complete repertoire of human and mouse
accessory proteins and growth factors in the chicken embryo, which could have potentially
modulated the phenotypes we observed. Finally, expertise with IV injections is a necessity
for the implantation procedure.
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4.2.3

Experimental metastasis model

The in vivo experimental metastasis model is a relevant model to investigate metastasis and
the interaction of molecules with the endothelium of blood vessels (Gomez-Cuadrado,
Tracey et al. 2017). The use of this experimental metastasis model allowed us to
specifically study the late stages of the metastatic cascade: the arrest and extravasation of
cancer cells into the lungs. Renal cell carcinoma preferentially metastasizes to the lungs,
so this model was relevant in understanding the effect of KIM-1 expression during
extravasation.
A major limitation of the experimental metastasis assay (the IV tail injection model
specifically) when it comes to studying metastasis is that it only recapitulates the late stages
of the metastatic cascade; arrest and extravasation out of the capillaries into the lungs
(Gomez-Cuadrado, Tracey et al. 2017). This assay evaluates how cancer cells grow in
ectopic sites but cannot account for how the primary tumour develops and invades into the
vasculature.

4.2.4

Spontaneous metastasis model

The spontaneous metastasis model implants the cancer cells orthotopically and overcomes
some of the limitations of the experimental model. It mimics the human disease and allows
for the development of the primary tumour and its dissemination to secondary sites
(Gomez-Cuadrado, Tracey et al. 2017). However, a drawback is that the earliest steps of
tumour formation cannot be assessed as the tumours do not spontaneously arise. Transgenic
mice allow for the autochthonous development of tumours which recapitulate the entire
metastatic cascade and allow for the study of cancer progression using experimental
models (Kabeer, Beverly et al. 2016, Gomez-Cuadrado, Tracey et al. 2017). For example,
mice engineered with a mutant p53 gene develop normally but are prone to spontaneous
tumour formation (Donehower, Harvey et al. 1992). Alternative methods utilize the Cre
recombinase/lox P system to activate specific oncogenes or inactivate specific tumour
suppressors and control the timing for tumour initiation (Jackson, Willis et al. 2001,
Gomez-Cuadrado, Tracey et al. 2017). Lox P recombination sites flank genes of interest
through homologous recombination, which can then be excised when the Cre recombinase
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is activated (Gu, Zou et al. 1993). A second limitation is that murine kidneys are quite
small, so expertise is required when injecting the cells under the subcapsular space to avoid
leakage of cells under the capsule or out of the kidneys. Furthermore, it is impossible to
measure the growth of the primary tumour using typical caliper measurements, so BLI will
have to be used to quantify tumour growth and dissemination via fluorescent protein signal
intensity.

4.2.5

Rag1-/- mice in an experimental metastasis model

Rag1-/- mice lack a functional recombination activation gene (RAG), which prevents them
from activating V(D)J recombination early on during T and B cell development
(Mombaerts, Iacomini et al. 1992). This recombination is critical to the differentiation of
T and B cells, and a deficiency results in mice that have underdeveloped lymphoid organs
which lack mature T and B lymphocytes. These mutant mice lack a functional adaptive
immune system, thus any observed differences in phenotype can be attributed to KIM-1
expression, and not adaptive immunity.
A major limitation of using Rag1-/- mice is that it knocks out the adaptive immune system
(T and B cells) but have an intact natural killer (NK) cell population. NK cells are
classically considered innate cells and thought to be activated in response to missing MHC
class I molecules on virus-infected or cancer cells, and induce adaptive immune cell
activation (Vivier, Tomasello et al. 2008). It has been suggested that NK cells possess antitumour properties and inhibit tumour growth and progression early on through various
pathways including Fas ligand and granzyme-family proteases. Some studies have shown
however, that although NK cells are still present in Rag1-deficient mice, Rag proteins are
essential for the functional development and survival of NK cells (Andrews and Smyth
2010, Karo, Schatz et al. 2014). Thus, the Rag1-/- mouse model serves its purpose of
studying the effect of the adaptive immune system in KIM-1-mediated inhibition of
metastasis. An alternative method would be to perform T and B cell depletion to verify that
the observed phenotypes are indeed a result of KIM-1 expression, rather than the adaptive
immune system.
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4.3 Future Directions and Significance
The implications of our findings within the context of the known literature suggests that
KIM-1 expression within tumours may have a paradoxical effect between tumour growth
and metastatic ability. On one hand, KIM-1 expression in the tumour promotes
proliferation and angiogenesis. On the other hand, KIM-1 expression inhibits the metastasis
of the primary tumour cells to distant organs. Although the literature predominantly points
towards KIM-1 as tumourigenic, there is evidence to support our data and reconcile the
two sides of the coin. A study by Cuadros et. al. (2013) investigated the effect of KIM-1
ectodomain shedding on the invasive capacity of 786-O cells and found that increased
shedding ability was directly associated with increased invasiveness and tumour
malignancy (Cuadros, Trilla et al. 2013). Their results suggest that surface expression of
KIM-1 inhibits invasive properties of RCC cells. An earlier study by Guo et. al. (2012)
engineered HT1080 cells that expressed KIM-1, or KIM-1 with a mutated juxtamembrane
region which was resistant to shedding by membrane-type-1 matrix metalloprotease (MT1MMP) (Guo, Takino et al. 2012). They found that the HT1080/KIM-1 cells had their KIM1 actively cleaved by MT1-MMP, which resulted in significantly increased cell adhesion,
invasive growth, and metastasis compared with HT1080/ΔKIM-1 cells. Together with
these studies, our work may pave the way for a new hypothesis: although KIM-1
exacerbates tumour growth and progression, the active cleavage of KIM-1 may allow
disseminated cancer cells to arrest and invade secondary tissues more efficiently. KIM-1
is overexpressed in >90% of RCC tumours and over a third of patients present with
metastases – the primary cause of death in patients with RCC – at the time of diagnosis
(Canadian Cancer Society 2015). These facts coupled with our data that indicates KIM-1
inhibits metastasis suggest that KIM-1 is potentially cleaved off RCC cells during their
dissemination into the vasculature.
Future work will be aimed at optimizing the spontaneous metastasis model and using
Renca-Luciferase cell lines to visualize and quantify tumour growth and metastatic spread
via BLI. Optimizing the spontaneous metastasis model will allow us to determine whether
the observed phenotypes in the experimental metastasis model are consistently expressed.
It will also illuminate whether Kim-1 on RCC cells is shed during its dissemination to the
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lungs in a mouse model. We will also explore the effect of anti-Kim-1 antibodies on the
development of metastatic lung nodules within both the experimental and spontaneous
metastasis model to determine whether blocking Kim-1 in mice injected with Kim-1+ cells
will abrogate Kim-1-mediated inhibition of metastasis. Furthermore, Rap1 and Rab27B
will be investigated in more detail to determine whether silencing these genes in Kim-1neg
Renca cells can block metastasis, and whether Kim-1 inhibits these GTPases like Gα12.
Future research could help elucidate the precise mechanism of KIM-1 inhibition and
develop specific antagonists that interact with the downstream effectors of KIM-1 in hopes
of treating metastatic RCC in patients.

4.4 Conclusion
Our results represent a novel discovery which unveils new perspectives on the relationship
between KIM-1 and RCC disease progression. In this study, we hypothesized that KIM-1
expression on RCC cells inhibits their ability to invade and metastasize and our findings
are supported by human clinical data (National Cancer Institute 2006). In summary, our
work has provided a clearer understanding on the role of KIM-1 in the invasion and
metastasis of RCC, and has ultimately provided evidence in support of our hypothesis. We
have demonstrated that KIM-1 expression inhibits invasion of Renca and 786-O cells in
vitro. We have highlighted the inhibitory effect of KIM-1 on the extravasation efficiency
of Renca and 769-P cells in an in vivo CAM model. We have shown that KIM-1 expression
inhibits metastasis in Renca and 786-O cells, and that this inhibitory effect occurs
independently from the adaptive immune system. Additionally, we have identified two
putative genes (Rap1 and Rab27B) involved in invasion, adhesion, and metastasis that may
be regulated by Kim-1. Continued research on the role of KIM-1 in metastatic RCC is
likely to substantially enhance our understanding of the pathogenesis of metastatic disease
and lead to the development of novel therapeutic targets. The extent of the role that KIM1 plays in the metastatic cascade of RCC – of which has previously not been studied or
discussed within the literature – has thus far been incompletely understood.
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Appendices
Appendix A 1: Overall survival between RCC patients with high or low HAVCR1
expression based on data from TCGA RNA-seq database.
A

B

Supplemental Figure 1. Overall survival between RCC patients with high or low
HAVCR1 expression based on data from TCGA RNA-seq database. In renal cell
carcinoma (RCC), expression of HAVCR1 is significantly upregulated in patient specimens
but low expression of HAVCR1 is significantly associated with poor prognosis of RCC
patients (P = 0.0034) based on data in The Cancer Genome Atlas. A) HAVCR1 mRNA
levels in 72-paired tumour and non-tumour margin tissue specimens of RCC patients
obtained from TCGA gene expression profiling datasets are shown. mRNA levels are
expressed as individually in tumour vs. non-tumour for each patient. B) Kaplan-Meier 10years (left) or 5-years (right) overall survival curves according to lower versus higher 30%
mRNA expression level of HAVCR1 in TCGA RCC patients.
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Appendix A 2: Fekete's Solution

Appendix A 3: Western blots of murine Kim-1 knock-in in the Renca cell line
A

B

Supplemental Figure 3. Western blots of murine Kim-1 knock-in in the Renca cell
line. Renca cells, which do not endogenously express Kim-1, were transfected with either
pCDEF3 or pCDEF3-mKim-1 plasmids. A) Protein expression in cell lysates from
pCDEF3 and pCDEF3-mKim-1 transfected Renca cells were compared to the endogenous
protein level of mKim-1 in primary PTECs isolated from WT C57BL/6 mice and to HEK293 cells transfected with the mKim-1 plasmid. B) Renca-pCDEF3 mKim-1 (2) and RencapCDEF3 (2) were subjected to G418 selection (400 μg/ml) to select for stable clones
expressing mKim-1 or the control plasmid, respectively. Protein lysates from respective
Renca clones were compared to the endogenous protein level of Kim-1 in primary PTECs
isolated from WT C57BL/6 mice and to HEK-293 cells transfected with the mKim-1
plasmid. WT, wild-type; mKim-1, murine Kim-1; C57BL/6 PTECs, primary proximal
tubular epithelial cells isolated from a WT C57BL/6 mouse following kidney injury.
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Appendix A 4: Murine Kim-1 expression in the Renca cell line
A

B

Supplemental Figure 4. Murine Kim-1 expression in the Renca cell line. Renca cells,
which do not endogenously express Kim-1, were transduced with either lentiviral particles
containing the Kim-1 transcript within the vector (Renca-mKim-1) or just the vector alone
(Renca-control) and then subjected to selection using puromycin (2 μg/ml) for generation
of stable cell lines. A) Western blot of protein expression in lysates from Renca-mKIM-1
cells at different MOIs and Renca-control cells (MOI of 60) were compared to the
endogenous protein level of mKim-1 in primary PTECs isolated from WT C57BL/6 mice
and to HEK-293 cells transfected with the pCDEF3-mKim-1 plasmid. B) mRNA
expression levels of Kim-1 in Renca-mKim-1 and Renca-control cells transduced with a
MOI of 60 were compared to the endogenous mRNA expression level of mKim-1 in
primary PTECs isolated from WT C57BL/6 mice using standard PCR as described in the
materials and methods. Normalization was performed to GAPDH. WT, wild-type; mKim1, murine Kim-1; MOI, multiplicity of infection; C57BL/6 PTECs, primary proximal
tubular epithelial cells isolated from a WT C57BL/6 mouse following kidney injury.
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Appendix A 5: Human KIM-1 knock-down in 769-P cell line
A

B

Supplemental Figure 5. Human Kim-1 knockdown in the 769-P cell line. 769-P cells,
which endogenously express high levels of KIM-1, were transduced with either lentiviral
particles containing KIM-1-specific constructs encoding shRNA (shKIM-1) or a scrambled
shRNA sequence (shcontrol). A) Protein expression in cell lysates from shcontrol and
shKIM-1 were compared to the endogenous protein expression level of KIM-1 (769-P WT)
by western blotting using antibodies against KIM-1 (extracellular domain) and β-actin. B)
Relative mRNA expression levels of KIM-1 from total RNA extracted from shcontrol and
shKIM-1 cells using real time-PCR (RT-PCR) (n = 9; *** = p < 0.0001). Normalization of
KIM-1 was performed to GAPDH and expressed as a fold change. Data is shown as mean
± SEM in the graph. WT, wild-type; hKIM-1, human KIM-1.
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